Banque Pictet & Cie SA Has $10.25 Million Holdings in DexCom, Inc. (NASDAQ:DXCM)

Banque Pictet & Cie SA boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 12.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 131,809 shares of the medical device company’s stock after purchasing an additional 14,419 shares during the period. Banque Pictet & Cie SA’s holdings in DexCom were worth $10,251,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Blue Whale Capital LLP lifted its position in DexCom by 91.9% during the 3rd quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock worth $15,821,000 after buying an additional 113,000 shares in the last quarter. Taylor Frigon Capital Management LLC grew its stake in shares of DexCom by 51.6% during the third quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock valued at $2,182,000 after purchasing an additional 11,075 shares during the last quarter. Brooktree Capital Management acquired a new stake in shares of DexCom in the third quarter valued at approximately $683,000. National Pension Service raised its position in DexCom by 4.1% in the 3rd quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock worth $63,671,000 after purchasing an additional 37,363 shares during the last quarter. Finally, Intact Investment Management Inc. acquired a new position in DexCom during the 3rd quarter worth $650,000. Institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling

In other news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the transaction, the executive vice president now owns 83,526 shares of the company’s stock, valued at $7,259,244.66. The trade was a 2.44 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 42,342 shares of company stock valued at $3,628,069. Company insiders own 0.30% of the company’s stock.

DexCom Stock Up 0.3 %

NASDAQ:DXCM opened at $84.09 on Friday. The stock has a 50-day moving average price of $82.11 and a two-hundred day moving average price of $75.19. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The stock has a market cap of $32.85 billion, a price-to-earnings ratio of 50.35, a PEG ratio of 2.26 and a beta of 1.14.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 17.22% and a return on equity of 31.40%. As a group, equities analysts expect that DexCom, Inc. will post 1.69 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently commented on DXCM. Raymond James lowered their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research note on Friday, October 25th. Sanford C. Bernstein boosted their price objective on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Wells Fargo & Company raised their target price on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Oppenheimer dropped their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Finally, Royal Bank of Canada cut their price objective on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $98.41.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.